Cargando…

The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial

BACKGROUND: To assess the efficacy and safety of the herbal medicine, Weng-li-tong (WLT) as monotherapy or combined with tolterodine in women with overactive bladder (OAB). METHODS: A prospective, randomized, single-blind multi-center trial was performed which included 182 OAB patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Dong-dong, Lv, Jian-wei, Xie, Xin, Jin, Xing-wei, Lu, Mu-jun, Shao, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977724/ https://www.ncbi.nlm.nih.gov/pubmed/27503124 http://dx.doi.org/10.1186/s12894-016-0167-1

Ejemplares similares

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
por: Aziminekoo, Elham, et al.
Publicado: (2014)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study
por: Song, Cheryn, et al.
Publicado: (2006)

Dissimilar Effects of Tolterodine on Detrusor Overactivity in Awake Rats with Chemical Cystitis and Partial Bladder Outlet Obstruction
por: Jin, Long-Hu, et al.
Publicado: (2011)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study
por: Tang, Min, et al.
Publicado: (2023)

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
por: Van Kerrebroeck, Philip EV, et al.
Publicado: (2009)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Tolterodine extended release is well tolerated in older subjects
por: Griebling, T L, et al.
Publicado: (2009)

On the Absolute Stereochemistry of Tolterodine: A Circular Dichroism Study
por: Górecki, Marcin, et al.
Publicado: (2019)

AB078. Disease correlation and effects of pelvic floor muscle training on tolterodine based treatment for female primary overactive bladder syndrome
por: Huang, Xiao, et al.
Publicado: (2016)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Effects of Tamsulosin and Tolterodine on double J stent–related symptoms: A double-blind, randomized, placebo-controlled trial
por: Moradi, Mahmoudreza, et al.
Publicado: (2017)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions
por: Angelico, Patrizia, et al.
Publicado: (2005)

Tolterodine extended release in the treatment of male oab/storage luts: a systematic review
por: Gacci, Mauro, et al.
Publicado: (2014)

Formulation and evaluation of taste-masked oral disintegrating tablet containing tolterodine-loaded montmorillonite
por: Taymouri, Somayeh, et al.
Publicado: (2023)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

Tolterodine to Relieve Urinary Symptoms Following Transurethral Resection of the Prostate: A Double-Blind Placebo-Controlled Randomized Clinical Trial
por: Tehranchi, Ali, et al.
Publicado: (2014)

Response to Weng
por: Allegretti, Andrew S.
Publicado: (2021)

Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis
por: Azarfar, Anoush, et al.
Publicado: (2015)

A validated LC–MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study
por: Shaik, Rihana Parveen, et al.
Publicado: (2013)

A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial
por: Ghanavati, Parvin Mousavi, et al.
Publicado: (2020)

Isolation, Identification, and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in the Tolterodine Tartrate Formulation
por: Prakash, Lakkireddy, et al.
Publicado: (2015)

A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia
por: Cao, Yanwei, et al.
Publicado: (2016)

A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples
por: Yanamandra, Ramesh, et al.
Publicado: (2012)

Does Combination Therapy with Desmopressin and Tolterodine Improve the Treatment Outcomes of Patients with Monosymptomatic Nocturnal Enuresis? A Randomized Clinical Controlled Trial
por: Kazemi Rashed, Fahimeh, et al.
Publicado: (2013)

Efficient kinetic resolution in the asymmetric transfer hydrogenation of 3-aryl-indanones: applications to a short synthesis of (+)-indatraline and a formal synthesis of (R)-tolterodine
por: Park, Songsoon, et al.
Publicado: (2021)

Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial
por: Cai, Jian-Liang, et al.
Publicado: (2016)

Overactive Bladder Disease: The Urge for Better Therapies
por: Thomas, Lisa, et al.
Publicado: (2008)

Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis
por: Yi, Wei, et al.
Publicado: (2021)

Critical appraisal of tubular putative eumetazoans from the Ediacaran Weng'an Doushantuo biota
por: Cunningham, John A., et al.
Publicado: (2015)

Efficacy of Chuanxiong Ding Tong Herbal Formula Granule in the Treatment and Prophylactic of Migraine Patients: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial
por: Fu, Caihong, et al.
Publicado: (2012)

Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems
por: Meng, Lingfeng, et al.
Publicado: (2022)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tbva12g92ur5bhrfodnftbjj62